Omicron-induced interferon signaling prevents influenza A H1N1 and H5N1 virus infection

J Med Virol. 2023 Mar;95(3):e28686. doi: 10.1002/jmv.28686.

Abstract

Recent findings in permanent cell lines suggested that SARS-CoV-2 Omicron BA.1 induces a stronger interferon response than Delta. Here, we show that BA.1 and BA.5 but not Delta induce an antiviral state in air-liquid interface cultures of primary human bronchial epithelial cells and primary human monocytes. Both Omicron subvariants caused the production of biologically active types I (α/β) and III (λ) interferons and protected cells from super-infection with influenza A viruses. Notably, abortive Omicron infection of monocytes was sufficient to protect monocytes from influenza A virus infection. Interestingly, while influenza-like illnesses surged during the Delta wave in England, their spread rapidly declined upon the emergence of Omicron. Mechanistically, Omicron-induced interferon signaling was mediated via double-stranded RNA recognition by MDA5, as MDA5 knockout prevented it. The JAK/STAT inhibitor baricitinib inhibited the Omicron-mediated antiviral response, suggesting it is caused by MDA5-mediated interferon production, which activates interferon receptors that then trigger JAK/STAT signaling. In conclusion, our study (1) demonstrates that only Omicron but not Delta induces a substantial interferon response in physiologically relevant models, (2) shows that Omicron infection protects cells from influenza A virus super-infection, and (3) indicates that BA.1 and BA.5 induce comparable antiviral states.

Keywords: BA.1; BA.5; COVID-19; Delta; SARS-CoV-2; antiviral state; influenza; interferon; monocytes; super-infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents
  • COVID-19*
  • Humans
  • Influenza A Virus, H1N1 Subtype*
  • Influenza A Virus, H5N1 Subtype*
  • Influenza A virus*
  • Influenza, Human*
  • Interferons
  • Janus Kinase Inhibitors*
  • SARS-CoV-2

Substances

  • Interferons
  • Antiviral Agents
  • Janus Kinase Inhibitors